251 related articles for article (PubMed ID: 21738597)
21. Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study.
Bonora S; Calcagno A; Cometto C; Fontana S; Aguilar D; D'Avolio A; Gonzalez de Requena D; Maiello A; Dal Conte I; Lucchini A; Di Perri G
Infection; 2012 Feb; 40(1):69-75. PubMed ID: 22135137
[TBL] [Abstract][Full Text] [Related]
22. Cidofovir added to HAART improves virological and clinical outcome in AIDS-associated progressive multifocal leukoencephalopathy.
De Luca A; Giancola ML; Ammassari A; Grisetti S; Cingolani A; Paglia MG; Govoni A; Murri R; Testa L; Monforte AD; Antinori A
AIDS; 2000 Sep; 14(14):F117-21. PubMed ID: 11061646
[TBL] [Abstract][Full Text] [Related]
23. Frequency and phenotype of JC virus-specific CD8+ T lymphocytes in the peripheral blood of patients with progressive multifocal leukoencephalopathy.
Lima MA; Marzocchetti A; Autissier P; Tompkins T; Chen Y; Gordon J; Clifford DB; Gandhi RT; Venna N; Berger JR; Koralnik IJ
J Virol; 2007 Apr; 81(7):3361-8. PubMed ID: 17229701
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M;
N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645
[TBL] [Abstract][Full Text] [Related]
25. JC virus load in cerebrospinal fluid and transcriptional control region rearrangements may predict the clinical course of progressive multifocal leukoencephalopathy.
Delbue S; Elia F; Carloni C; Tavazzi E; Marchioni E; Carluccio S; Signorini L; Novati S; Maserati R; Ferrante P
J Cell Physiol; 2012 Oct; 227(10):3511-7. PubMed ID: 22253012
[TBL] [Abstract][Full Text] [Related]
26. Human polyomavirus JC latency and reactivation status in blood of HIV-1-positive immunocompromised patients with and without progressive multifocal leukoencephalopathy.
Andréoletti L; Dubois V; Lescieux A; Dewilde A; Bocket L; Fleury HJ; Wattré P
AIDS; 1999 Aug; 13(12):1469-75. PubMed ID: 10465069
[TBL] [Abstract][Full Text] [Related]
27. Progressive multifocal leukencephalopathy in patients on highly active antiretroviral therapy: survival and risk factors of death.
Wyen C; Hoffmann C; Schmeisser N; Wöhrmann A; Qurishi N; Rockstroh J; Esser S; Rieke A; Ross B; Lorenzen T; Schmitz K; Stenzel W; Salzberger B; Fätkenheuer G
J Acquir Immune Defic Syndr; 2004 Oct; 37(2):1263-8. PubMed ID: 15385733
[TBL] [Abstract][Full Text] [Related]
28. Analysis of PCR as a tool for detection of JC virus DNA in cerebrospinal fluid for diagnosis of progressive multifocal leukoencephalopathy.
Hammarin AL; Bogdanovic G; Svedhem V; Pirskanen R; Morfeldt L; Grandien M
J Clin Microbiol; 1996 Dec; 34(12):2929-32. PubMed ID: 8940424
[TBL] [Abstract][Full Text] [Related]
29. A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes.
Clifford DB; Nath A; Cinque P; Brew BJ; Zivadinov R; Gorelik L; Zhao Z; Duda P
J Neurovirol; 2013 Aug; 19(4):351-8. PubMed ID: 23733308
[TBL] [Abstract][Full Text] [Related]
30. Polyomavirus JCV excretion and genotype analysis in HIV-infected patients receiving highly active antiretroviral therapy.
Lednicky JA; Vilchez RA; Keitel WA; Visnegarwala F; White ZS; Kozinetz CA; Lewis DE; Butel JS
AIDS; 2003 Apr; 17(6):801-7. PubMed ID: 12660526
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of progressive multifocal leukoencephalopathy treatments in a Spanish cohort of HIV-infected patients: do protease inhibitors improve survival regardless of central nervous system penetration-effectiveness (CPE) score?
Fanjul F; Riveiro-Barciela M; Gonzalez J; Delgado E; Murillas J; Payeras Cifré A; Falcó V; Riera M
HIV Med; 2013 May; 14(5):321-5. PubMed ID: 23217049
[TBL] [Abstract][Full Text] [Related]
32. JCV-specific cellular immune response correlates with a favorable clinical outcome in HIV-infected individuals with progressive multifocal leukoencephalopathy.
Du Pasquier RA; Clark KW; Smith PS; Joseph JT; Mazullo JM; De Girolami U; Letvin NL; Koralnik IJ
J Neurovirol; 2001 Aug; 7(4):318-22. PubMed ID: 11517410
[TBL] [Abstract][Full Text] [Related]
33. [Clinical efficacy and tolerance of enfuvirtide (Fuzeon), new antiretroviral inhibitors of intracellular penetration of human immunodeficiency virus (HIV) type 1].
Raffi F
Med Mal Infect; 2004 Sep; 34 Spec No 1():8-17. PubMed ID: 15742550
[TBL] [Abstract][Full Text] [Related]
34. Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.
Perkins MR; Ryschkewitsch C; Liebner JC; Monaco MC; Himelfarb D; Ireland S; Roque A; Edward HL; Jensen PN; Remington G; Abraham T; Abraham J; Greenberg B; Kaufman C; LaGanke C; Monson NL; Xu X; Frohman E; Major EO; Douek DC
PLoS Pathog; 2012; 8(11):e1003014. PubMed ID: 23144619
[TBL] [Abstract][Full Text] [Related]
35. Treatment options for AIDS patients with progressive multifocal leukoencephalopathy.
Hernández B; Dronda F; Moreno S
Expert Opin Pharmacother; 2009 Feb; 10(3):403-16. PubMed ID: 19191678
[TBL] [Abstract][Full Text] [Related]
36. Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies.
Bellizzi A; Nardis C; Anzivino E; Rodìo D; Fioriti D; Mischitelli M; Chiarini F; Pietropaolo V
J Neurovirol; 2012 Feb; 18(1):1-11. PubMed ID: 22290500
[TBL] [Abstract][Full Text] [Related]
37. Remission of progressive multifocal leukoencephalopathy following highly active antiretroviral therapy in a patient with HIV infection.
Inui K; Miyagawa H; Sashihara J; Miyoshi H; Tanaka-Taya K; Nishigaki T; Teraoka S; Mano T; Ono J; Okada S
Brain Dev; 1999 Sep; 21(6):416-9. PubMed ID: 10487477
[TBL] [Abstract][Full Text] [Related]
38. Identical rearranged forms of JC polyomavirus transcriptional control region in plasma and cerebrospinal fluid of acquired immunodeficiency syndrome patients with progressive multifocal leukoencephalopathy.
Fedele CG; Ciardi MR; Delia S; Contreras G; Perez JL; De Oña M; Vidal E; Tenorio A
J Neurovirol; 2003 Oct; 9(5):551-8. PubMed ID: 13129769
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of JC virus viraemia in HIV-infected patients with or without neurological disorders: a prospective study.
Dubois V; Moret H; Lafon ME; Janvresse CB; Dussaix E; Icart J; Karaterki A; Ruffault A; Taoufik Y; Vignoli C; Ingrand D
J Neurovirol; 1998 Oct; 4(5):539-44. PubMed ID: 9839651
[TBL] [Abstract][Full Text] [Related]
40. Rearranged JC virus noncoding control regions found in progressive multifocal leukoencephalopathy patient samples increase virus early gene expression and replication rate.
Gosert R; Kardas P; Major EO; Hirsch HH
J Virol; 2010 Oct; 84(20):10448-56. PubMed ID: 20686041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
